JP2017537899A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537899A5
JP2017537899A5 JP2017526088A JP2017526088A JP2017537899A5 JP 2017537899 A5 JP2017537899 A5 JP 2017537899A5 JP 2017526088 A JP2017526088 A JP 2017526088A JP 2017526088 A JP2017526088 A JP 2017526088A JP 2017537899 A5 JP2017537899 A5 JP 2017537899A5
Authority
JP
Japan
Prior art keywords
compound
therapeutic agent
dissolution
formula
elution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537899A (ja
JP6829684B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061194 external-priority patent/WO2016081523A1/en
Publication of JP2017537899A publication Critical patent/JP2017537899A/ja
Publication of JP2017537899A5 publication Critical patent/JP2017537899A5/ja
Application granted granted Critical
Publication of JP6829684B2 publication Critical patent/JP6829684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526088A 2014-11-17 2015-11-17 癌を処置する方法 Active JP6829684B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US62/080,985 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US62/166,572 2015-05-26
US201562251903P 2015-11-06 2015-11-06
US62/251,903 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021008382A Division JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法

Publications (3)

Publication Number Publication Date
JP2017537899A JP2017537899A (ja) 2017-12-21
JP2017537899A5 true JP2017537899A5 (enExample) 2018-12-27
JP6829684B2 JP6829684B2 (ja) 2021-02-10

Family

ID=56014476

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017526088A Active JP6829684B2 (ja) 2014-11-17 2015-11-17 癌を処置する方法
JP2021008382A Pending JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法
JP2023027585A Active JP7485810B2 (ja) 2014-11-17 2023-02-24 癌を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021008382A Pending JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法
JP2023027585A Active JP7485810B2 (ja) 2014-11-17 2023-02-24 癌を処置する方法

Country Status (21)

Country Link
US (3) US10786511B2 (enExample)
EP (2) EP4272742A1 (enExample)
JP (3) JP6829684B2 (enExample)
KR (3) KR20240035908A (enExample)
CN (2) CN107249591B (enExample)
AU (3) AU2015350108B2 (enExample)
BR (1) BR112017010166A2 (enExample)
CA (1) CA2967664A1 (enExample)
DK (1) DK3220916T3 (enExample)
EA (1) EA201791095A1 (enExample)
ES (1) ES2947819T3 (enExample)
FI (1) FI3220916T3 (enExample)
HU (1) HUE062159T2 (enExample)
IL (4) IL296080B2 (enExample)
LT (1) LT3220916T (enExample)
MX (2) MX383484B (enExample)
PL (1) PL3220916T3 (enExample)
PT (1) PT3220916T (enExample)
SG (1) SG11201703806XA (enExample)
SI (1) SI3220916T1 (enExample)
WO (1) WO2016081523A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
BR112015008447A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc métodos para tratar câncer
WO2015085325A1 (en) 2013-12-06 2015-06-11 Epizyme, Inc. Combination therapy for treating cancer
KR20230031963A (ko) 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
KR20240035908A (ko) 2014-11-17 2024-03-18 에피자임, 인코포레이티드 암을 치료하기 위한 방법
WO2016172199A1 (en) 2015-04-20 2016-10-27 Epizyme, Inc. Combination therapy for treating cancer
CA2988816A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
JP7121660B2 (ja) 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
CA3050221C (en) 2017-01-19 2021-09-28 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of htlv-1-associated myelopathy
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
BR112022012258A2 (pt) * 2019-12-20 2022-08-30 Epizyme Inc Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
US20250146080A1 (en) * 2022-02-17 2025-05-08 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
IL316421A (en) 2022-04-27 2024-12-01 Daiichi Sankyo Co Ltd Combination of an antibody-drug conjugate with an EZH1 and/or EZH2 inhibitor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤、およびその使用方法
US20130296325A1 (en) * 2011-01-14 2013-11-07 Bristol-Myers Squibb Company HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CA2867282C (en) * 2012-03-12 2024-04-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
RU2699546C2 (ru) 2012-04-13 2019-09-06 Эпизайм, Инк. Комбинированная терапия для лечения рака
PL3184523T3 (pl) * 2012-04-13 2019-12-31 Epizyme Inc Bromowodorek N-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5- (etylo(tetrahydro-2H-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'- bifenylo]-3-karboksyamidu do zastosowania w leczeniu zaburzenia proliferacji komórkowej układu hematologicznego
SG10201705989YA (en) 2012-10-15 2017-08-30 Epizyme Inc Substituted benzene compounds
BR112015008447A2 (pt) * 2012-10-15 2017-07-04 Epizyme Inc métodos para tratar câncer
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
EP2935214B1 (en) 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
EP4324525A3 (en) 2013-10-16 2024-07-17 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
US20160228447A1 (en) * 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
WO2015085325A1 (en) 2013-12-06 2015-06-11 Epizyme, Inc. Combination therapy for treating cancer
KR20230031963A (ko) * 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CN106794177A (zh) 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
KR20240035908A (ko) 2014-11-17 2024-03-18 에피자임, 인코포레이티드 암을 치료하기 위한 방법
CA2988816A1 (en) * 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
MA45406A (fr) * 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer

Similar Documents

Publication Publication Date Title
JP2017537899A5 (enExample)
KR102338802B1 (ko) 암을 치료하기 위한 방법
JP2023036772A (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
DK2605757T3 (en) Nalbuphine-based formulations and applications thereof
US11065240B2 (en) Drug combinations to treat multiple myeloma
ES2811110T3 (es) Composición farmacéutica capaz de la incorporación de Lenalidomida en diversas modificaciones cristalinas
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
KR102490547B1 (ko) 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
JP2024009815A (ja) アキシチニブを含有する医薬組成物
WO2017075576A1 (en) Eflornithine and sulindac, fixed dose combination formulation
JP2013536243A5 (enExample)
RU2712187C2 (ru) Фармацевтические композиции и их применение
TWI606826B (zh) 艾拉莫德或其鹽之用途
ES2792574T3 (es) Formulación de Ceritinib
JP2015534985A5 (enExample)
JP7370126B2 (ja) エルロチニブを有効成分とする医薬錠剤
WO2011081118A1 (ja) 経口投与用医薬組成物
JP2020075924A (ja) エルロチニブを有効成分とする医薬錠剤
JP2020090456A (ja) エルロチニブを有効成分とする医薬錠剤
JP2018020968A (ja) ゲフィチニブを有効成分とする医薬組成物
JPWO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
EA048689B1 (ru) Твердый фармацевтический состав для лечения рака
TW201726124A (zh) 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物
RU2012135961A (ru) Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения